Edition:
India

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.68USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
91,282
52-wk High
$4.68
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Imprimis Pharmaceuticals Q3 loss per share $‍0.28​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis Pharmaceuticals announces third quarter 2017 results.Q3 revenue rose 34 percent to $6.5 million.Imprimis Pharmaceuticals inc qtrly loss per share $‍0.28​.  Full Article

Imprimis Pharmaceuticals implemented an expense reduction program
Monday, 26 Sep 2016 

Imprimis Pharmaceuticals Inc : Co implemented an expense reduction program . Has ceased operations at its Texas facility and implemented an 8% reduction in total headcount . Exploring alternatives for use of Texas facility, estimates will incur total restructuring costs of about $0.6 million under plan .Actions are expected to streamline Imprimis' operations and reduce expected cash based expenses by nearly $3 million annually.  Full Article

Imprimis Pharmaceuticals Q2 revenue $4.9 million
Tuesday, 16 Aug 2016 

Imprimis Pharmaceuticals Inc : Imprimis pharmaceuticals announces second quarter 2016 financial results . Q2 revenue rose 150 percent to $4.9 million .Qtrly net loss per common share $0.35.  Full Article

Imprimis Pharmaceuticals $2 mln sale agreement with Essex Capital
Thursday, 11 Aug 2016 

Imprimis Pharmaceuticals Inc : Agreement covers sale and leaseback of Imprimis' drug manufacturing equipment and has an initial term of up to three years . Agreement covers an additional one-year lease extension, subject to Imprimis achieving certain financial milestones .Imprimis Pharmaceuticals announces $2 million equipment sale leaseback agreement with Essex Capital Corporation.  Full Article

Imprimis Pharmaceuticals Q1 loss per share $0.43
Friday, 13 May 2016 

Imprimis Pharmaceuticals Inc : Q1 loss per share $0.43 . Imprimis pharmaceuticals announces first quarter 2016 financial results and provides business update .Q1 revenue $4.4 million versus $1.6 million.  Full Article

Imprimis Pharmaceuticals, Inc announces pricing of public offering of common stock
Friday, 11 Mar 2016 

Imprimis Pharmaceuticals, Inc:Pricing of an underwritten public offering of 2.9 million shares of its common stock at a price to the public of $3.60 per share, before underwriting discounts.Offering is expected to close on or about March 16, 2016, subject to satisfaction of customary closing conditions.  Full Article